Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia.
- Author:
Yi SONG
1
;
Ning-chen LI
;
Xiao-feng WANG
;
Lu-lin MA
;
Ben WAN
;
Bao-fa HONG
;
Yan-qun NA
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Drug Combinations; Ethamsylate; adverse effects; therapeutic use; Humans; Male; Middle Aged; Plant Extracts; adverse effects; therapeutic use; Prostatic Hyperplasia; drug therapy; Quality of Life; Treatment Outcome; Urodynamics
- From: National Journal of Andrology 2005;11(9):674-676
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the efficacy and safety of Eviprostat for the treatment of benign prostatic hyperplasia (BPH).
METHODSAn open, multicentral clinical trial was conducted in 100 patients with BPH. Patients received a 12-week oral administration of Eviprostat 2 tablets per-time, 3 times a day. The main indexes of efficacy include international prostatic symptom score (IPSS), maximum urinary flow rate (Qmax), residual urine ( Ru) and prostatic volume (V). The additional indexes are quality of life score (QOL) and average urinary flow rate (Qave).
RESULTSAfter a 12-week therapy, IPSS, QOL score, Qmax and Qave were significantly improved. IPSS was averagely decreased by 5.67 (P < 0.001); QOL score was averagely decreased by 1.44 (P < 0.001); Qmax was averagely increased by 1.70 ml/s (P <0.001); Qave was averagely increased by 1.15 ml/s (P < 0.001); Ru was averagely decreased by 5.07 ml (P = 0.046) , PSA level was averagely decreased by 0.129 microg/L (P < 0.017). The clinical adverse event rate was 1%.
CONCLUSIONEviprostat is a kind of safe, effective and preferable drug for treating BPH. It can improve the subjective symptoms and objective measures of the patients.
